From 2020 to 2021: Thoughts from PSI CRO
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

From 2020 to 2021: Thoughts from PSI CRO

Christian Buhlmann, Head of Business Development Europe & APAC, PSI CROChristian Buhlmann, Head of Business Development Europe & APAC,PSI CRO
If 2020 taught us anything, it’s that we can’t predict the future. In clinical research and the pharmaceutical industry specifically, organizations have to be ready to adapt, adjust, and change at a moment’s notice to stay up to speed – pandemic or not.

In the past year, the industry saw significant changes in technology adoption, patient centricity, and remote access to sites. Trial continuity depended deeply on not only these aspects, but also on the staff and teams that were required to flex quickly to support those changes. Simply put, 2020 forced the industry to make leaps and bounds towards the goals that many of us were dreaming of for years.

In 2021 we have to be ready to adapt, adjust, and change again.
We have to dive deep to refine the processes that the industry grabbed ahold of in 2020 without dropping any standards of project delivery or customer service. Organizations that aren’t able to flex will struggle, and trials that aren’t managed accordingly will be delayed. But, organizations that are nimble, hold a truly global footprint, and have experienced teams in place will shine. CROs that are already dedicated to on-time delivery and service will see that dedication grow even stronger. And because of the clinical development conversation and education that’s risen from COVID-19, trials will be considered as a primary health care option more and more.

At PSI, we’ve seen significant growth in 2020 that will continue into 2021 and beyond. We’ve stayed true to our values as a privately owned, global CRO, and we’ve shifted many processes in order to adapt to the changing clinical space in a very short amount of time. Not only are we ready for another fast-paced, patient-focused year – we’re excited for it. We’re excited to help bring more drugs to market, we’re excited to continue partnering with pharma and biotech teams to put patients first, and we’re excited to continue adopting new processes and flexing quickly to deliver on-time. While we can’t predict the exact changes or disruptions that might take place, we’re excited for how we’ll handle the ever-shifting landscape in order to get care to the patients that need it.
Share this Article:
Top 10 CROs in APAC - 2020